ADVATE Hemophilia A Outcome Database
Phase of Trial: Phase IV
Latest Information Update: 18 Oct 2017
At a glance
- Drugs Rurioctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Therapeutic Use
- Acronyms AHEAD
- Sponsors Baxalta; Baxter Healthcare Corporation
- 10 Jun 2017 Biomarkers information updated
- 06 Dec 2016 Interim results of 3 year follow-up of patients with severe and moderate Hemophilia A (n=522) enrolled in the AHEAD study, presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
- 09 Oct 2015 Planned number of patients changed from 350 to 500, according to ClinicalTrials.gov record.